Nature Communications (Jan 2023)

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

  • R. C. Coombes,
  • P. D. Badman,
  • J. P. Lozano-Kuehne,
  • X. Liu,
  • I. R. Macpherson,
  • I. Zubairi,
  • R. D. Baird,
  • N. Rosenfeld,
  • J. Garcia-Corbacho,
  • N. Cresti,
  • R. Plummer,
  • A. Armstrong,
  • R. Allerton,
  • D. Landers,
  • H. Nicholas,
  • L. McLellan,
  • A. Lim,
  • F. Mouliere,
  • O. E. Pardo,
  • V. Ferguson,
  • M. J. Seckl

DOI
https://doi.org/10.1038/s41467-023-35969-4
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 1

Abstract

Read online

No abstracts available.